3030 Bunker Hill Street, Suite 4000 San Diego CA 92109 USA
Aethlon Medical is the developer of the Hemopurifier, a medical device to treat infectious disease.
The Hemopurifier addresses the treatment of drug and vaccine resistant viruses.
Regulatory and commercialisation initiatives in the USA are focused on bioterror threats, while international initiatives are directed towards naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV).
The United States Food and Drug Administration (FDA) approves an Investigational Device Exemption (IDE) that allows Aethlon Medical to initiate human feasibility studies of the Aethlon Hemopurifier in the USA.
The Defense Advanced Research Projects Agency (DARPA) is exercising an option agreement to proceed with year-two of a five-year $6.8 million contract that was awarded to Aethlon Medical on September 30, 2011 under DARPA's Dialysis-Like Therapeutics (DLT) programme.
Researchers from Morehouse School of Medicine are showing that the Aethlon Hemopurifier is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS).
Aethlon Medical is reporting that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifier to capture tumour-secreted exosomes from the blood of advanced-stage cancer patients has received institutional review board approval to begin studies at the Sarcoma Oncology Center, based in Santa Monica, California, USA.
Aethlon Medical is awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers.
Aethlon Medical is introduicng HER2osome, a novel medical device strategy to inhibit the progression of HER2+ breast cancer, which is characterized by aggressive growth and poor prognosis resulting from the over-expression of HER2 protein.
Aethlon Medical, the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, enters into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.
Aethlon Medical's wholly owned subsidiary Exosome Sciences (ESI) validates the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.
Aethlon Medical, the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, is demonstrating the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.
The Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) approves a treatment programme entitled: 'Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy.'
Aethlon Medical is filing a provisional patent on behalf of its wholly owned subsidiary Exosome Sciences (ESI), relating to the development of an assay that will allow researchers to detect exosomes in blood and other fluids.
Aethlon Medical releases new data resulting from its recent ′first-in-human’ application of the Aethlon Hemopurifier to treat Human Immunodeficiency Virus (HIV), the disease that causes Acquired Immune Deficiency Syndrome (AIDS).
Aethlon Medical and Delcath Systems have agreed to collaborate on research and development of an advanced filtration cartridge for potential use in Delcath Systems’ percutaneous hepatic perfusion (PHP) system.